Histone-modifier gene expression profiles are associated with pathological and clinical outcomes in human breast cancer

Anticancer Research

Volumn 31, Issue 12, 2011, Pages 4115-4126

  Patani, Neill ^a   Jiang, Wen G ^b   Newbold, Robert F ^c   Mokbel, Kefah ^a,c  

^a Princess Grace Hospital   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c BRUNEL UNIVERSITY   (United Kingdom)

Author keywords

Breast cancer; Epigenetic regulation; Histone acetyltransferases; Histone methyltransferases; Histone modifier genes

Indexed keywords

CAMP RESPONSE ELEMENT BINDING PROTEIN BINDING PROTEIN; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 5; K ACETYLTRANSFERASE 2B; K ACETYLTRANSFERASE 5; K ACETYLTRANSFERASE 8; LYSINE SPECIFIC DEMETHYLASE 1A; LYSINE SPECIFIC DEMETHYLASE 4A; LYSINE SPECIFIC DEMETHYLASE 5C; LYSINE SPECIFIC DEMETHYLASE 6A; MIXED LINEAGE LEUKEMIA PROTEIN; PROTEIN; SET AND MYND DOMAIN CONTAINING 3 PROTEIN; SET DOMAIN CONTAINING SUPPRESSOR OF VARIEGATION 3-9 HOMOLOG 1 PROTEIN; SET DOMAIN CONTAINING SUPPRESSOR OF VARIEGATION 3-9 HOMOLOG 2 PROTEIN; SIRTUIN 1; UNCLASSIFIED DRUG;

ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER SURVIVAL; CANCER TISSUE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FOLLOW UP; GENE EXPRESSION; GENETIC TRANSCRIPTION; HISTONE MODIFICATION; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION; RNA EXTRACTION; TUMOR VOLUME;

BREAST NEOPLASMS; CHROMATIN; CPG ISLANDS; CYTOSINE; DNA PRIMERS; DNA, COMPLEMENTARY; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE ACETYLTRANSFERASES; HISTONE-LYSINE N-METHYLTRANSFERASE; HISTONES; HUMANS; NUCLEOTIDES; RNA; TREATMENT OUTCOME;

EID: 84855168980     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Lund AH and van Lohuizen M: Epigenetics and cancer. Genes Dev 18(19): 2315-2335, 2004. (Pubitemid 39310518)
2. Santos-Rosa H and Caldas C: Chromatin modifier enzymes, the histone code and cancer. Eur J Cancer 41(16): 2381-2402, 2005. (Pubitemid 41540617)
3. Ozdag H, Teschendorff AE, Ahmed AA, Hyland SJ, Blenkiron C, Bobrow L, Veerakumarasivam A, Burtt G, Subkhankulova T, Arends MJ, Collins VP, Bowtell D, Kouzarides T, Brenton JD and Caldas C: Differential expression of selected histone modifier genes in human solid cancers. BMC Genomics 7: 90, 2006.
4. Kouzarides T: Chromatin modifications and their function. Cell 128(4): 693-705, 2007.
5. Wang GG, Allis CD and Chi P: Chromatin remodeling and cancer, Part I: Covalent histone modifications. Trends Mol Med 13(9): 363-372, 2007. (Pubitemid 47385381)
6. Khorasanizadeh S: The nucleosome: from genomic organization to genomic regulation. Cell 116(2): 259-272, 2004.
7. Jenuwein T and Allis CD: Translating the histone code. Science 293(5532): 1074-1080, 2001. (Pubitemid 32758077)
8. Jovanovic J, Ronneberg JA, Tost J and Kristensen V: The epigenetics of breast cancer. Mol Oncol 4(3): 242-254, 2010.
9. Lachner M, O'Sullivan RJ, and Jenuwein T: An epigenetic road map for histone lysine methylation. J Cell Sci 116(Pt 11): 2117-2124, 2003. (Pubitemid 36722358)
10. Kurdistani SK: Histone modifications as markers of cancer prognosis: a cellular view. Br J Cancer 97(1): 1-5, 2007.
11. Ronneberg JA, Fleischer T, Solvang HK, Nordgard SH, Edvardsen H, Potapenko I, Nebdal D, Daviaud C, Gut I, Bukholm I, Naume B, Borresen-Dale AL, Tost J and Kristensen V: Methylation profiling with a panel of cancer related genes: association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer. Mol Oncol 5(1): 61-76, 2011.
12. Soares J, Pinto AE, Cunha CV, Andre S, Barao I, Sousa JM and Cravo M: Global DNA hypomethylation in breast carcinoma: correlation with prognostic factors and tumor progression. Cancer 85(1): 112-118, 1999. (Pubitemid 29031364)
13. Li S, Rong M and Iacopetta B: DNA hypermethylation in breast cancer and its association with clinicopathological features. Cancer Lett 237(2): 272-280, 2006. (Pubitemid 43792523)
14. Elsheikh SE, Green AR, Rakha EA, Powe DG, Ahmed RA, Collins HM, Soria D, Garibaldi JM, Paish CE, Ammar AA, Grainge MJ, Ball GR, Abdelghany MK, Martinez-Pomares L, Heery DM and Ellis IO: Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res 69(9): 3802-3809, 2009.
15. Gayther SA, Batley SJ, Linger L, Bannister A, Thorpe K, Chin SF, Daigo Y, Russell P, Wilson A, Sowter HM, Delhanty JD, Ponder BA, Kouzarides T and Caldas C: Mutations truncating the EP300 acetylase in human cancers. Nat Genet 24(3): 300-303, 2000. (Pubitemid 30132203)
16. Kawai H, Li H, Avraham S, Jiang S and Avraham HK: Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha. Int J Cancer 107(3): 353-358, 2003. (Pubitemid 37266453)
17. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, Rubin MA and Chinnaiyan AM: EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 100(20): 11606-11, 2003. (Pubitemid 37205983)
18. Berger SL: Histone modifications in transcriptional regulation. Curr Opin Genet Dev 12(2): 142-148, 2002.
19. Al Sarakbi W, Sasi W, Jiang WG, Roberts T, Newbold RF and Mokbel K: The mRNA expression of SETD2 in human breast cancer: correlation with clinicopathological parameters. BMC Cancer 9: 290, 2009.
20. Thiagalingam S, Cheng KH, Lee HJ, Mineva N, Thiagalingam A and Ponte JF: Histone deacetylases: unique players in shaping the epigenetic histone code. Ann N Y Acad Sci 983: 84-100, 2003. (Pubitemid 36399322)
21. Jiang WG, Watkins G, Lane J, Cunnick GH, Douglas-Jones A, Mokbel K and Mansel RE: Prognostic value of rho GTPases and rho guanine nucleotide dissociation inhibitors in human breast cancers. Clin Cancer Res 9(17): 6432-6440, 2003. (Pubitemid 38031830)
22. Cameron EE, Bachman KE, Myohanen S, Herman JG and Baylin SB: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21(1): 103-107, 1999. (Pubitemid 29036293)
23. Suzuki J, Chen YY, Scott GK, Devries S, Chin K, Benz CC, Waldman FM and Hwang ES: Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression. Clin Cancer Res 15(9): 3163-3171, 2009.
24. Wang Z, Zang C, Cui K, Schones DE, Barski A, Peng W and Zhao K: Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell 138(5): 1019-1031, 2009.
25. Taipale M, Rea S, Richter K, Vilar A, Lichter P, Imhof A and Akhtar A: hMOF histone acetyltransferase is required for histone H4 lysine 16 acetylation in mammalian cells. Mol Cell Biol 25(15): 6798-6810, 2005. (Pubitemid 41023250)
26. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K, Iyer NG, Perez-Rosado A, Calvo E, Lopez JA, Cano A, Calasanz MJ, Colomer D, Piris MA, Ahn N, Imhof A, Caldas C, Jenuwein T and Esteller M: Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37(4): 391-400, 2005.
27. Pfister S, Rea S, Taipale M, Mendrzyk F, Straub B, Ittrich C, Thuerigen O, Sinn HP, Akhtar A and Lichter P: The histone acetyltransferase hMOF is frequently down-regulated in primary breast carcinoma and medulloblastoma and constitutes a biomarker for clinical outcome in medulloblastoma. Int J Cancer 122(6): 1207-1213, 2008. (Pubitemid 351287218)
28. Kapoor-Vazirani P, Kagey JD, Powell DR and Vertino PM: Role of hMOF-dependent histone H4 lysine 16 acetylation in the maintenance of TMS1/ASC gene activity. Cancer Res 68(16): 6810-6821, 2008.
29. Conway KE, McConnell BB, Bowring CE, Donald CD, Warren ST and Vertino PM: TMS1, a novel proapoptotic caspase recruitment domain protein, is a target of methylation-induced gene silencing in human breast cancers. Cancer Res 60(22): 6236-6242, 2000.
30. Parsons MJ, Patel P, Brat DJ, Colbert L and Vertino PM: Silencing of TMS1/ASC promotes resistance to anoikis in breast epithelial cells. Cancer Res 69(5): 1706-1711, 2009.
31. Li X, Wu L, Corsa CA, Kunkel S and Dou Y: Two mammalian MOF complexes regulate transcription activation by distinct mechanisms. Mol Cell 36(2): 290-301, 2009.
32. Lim S, Janzer A, Becker A, Zimmer A, Schule R, Buettner R and Kirfel J: Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis 31(3): 512-520, 2010.
33. Bradley C, van der Meer R, Roodi N, Yan H, Chandrasekharan MB, Sun ZW, Mernaugh RL, and Parl FF: Carcinogen-induced histone alteration in normal human mammary epithelial cells. Carcinogenesis 28(10): 2184-2192, 2007. (Pubitemid 47543380)
34. Huang J, Sengupta R, Espejo AB, Lee MG, Dorsey JA, Richter M, Opravil S, Shiekhattar R, Bedford MT, Jenuwein T and Berger SL: p53 is regulated by the lysine demethylase LSD1. Nature 449(7158): 105-108, 2007. (Pubitemid 47373772)
35. Hu Q, Kwon YS, Nunez E, Cardamone MD, Hutt KR, Ohgi KA, Garcia-Bassets I, Rose DW, Glass CK, Rosenfeld MG and Fu XD: Enhancing nuclear receptor-induced transcription requires nuclear motor and LSD1-dependent gene networking in interchromatin granules. Proc Natl Acad Sci USA 105(49): 19199-19204, 2008.
36. Aagaard L, Laible G, Selenko P, Schmid M, Dorn R, Schotta G, Kuhfittig S, Wolf A, Lebersorger A, Singh PB, Reuter G and Jenuwein T: Functional mammalian homologues of the Drosophila PEV-modifier Su(var)3-9 encode centromere- associated proteins which complex with the heterochromatin component M31. EMBO J 18(7): 1923-1938, 1999. (Pubitemid 29158536)
37. Rea S, Eisenhaber F, O'Carroll D, Strahl BD, Sun ZW, Schmid M, Opravil S, Mechtler K, Ponting CP, Allis CD and Jenuwein T: Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature 406(6796): 593-599, 2000. (Pubitemid 30641039)
38. Vaquera A, Scher M, Erdjument-Bromage H, Tempst P, Serrano L and Reinberg D: SIRT1 regulates the histone methyltransferase SUV39H1 during heterochromatin formation. Nature 450(7168): 440-444, 2007. (Pubitemid 350126745)
39. Li Z, Chen L, Kabra N, Wang C, Fang J and Chen J: Inhibition of SUV39H1 methyltransferase activity by DBC1. J Biol Chem 284(16): 10361-10366, 2009.
40. Macaluso M, Cinti C, Russo G, Russo A and Giordano A: pRb2/p130-E2F4/5-HDAC1-SUV39H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 multimolecular complexes mediate the transcription of estrogen receptor-alpha in breast cancer. Oncogene 22(23): 3511-3517, 2003. (Pubitemid 36765310)
41. Leader JE, Wang C, Popov VM, Fu M and Pestell RG: Epigenetics and the estrogen receptor. Ann NY Acad Sci 1089: 73-87, 2006. (Pubitemid 47092100)
42. Yang X, Ferguson AT, Nass SJ, Phillips DL, Butash KA, Wang SM, Herman JG and Davidson NE: Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. Cancer Res 60(24): 6890-6894, 2000. (Pubitemid 32059160)
43. Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG and Davidson NE: Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res 61(19): 7025-7029, 2001. (Pubitemid 32946489)
44. Sun JM, Chen HY and Davie JR: Effect of estradiol on histone acetylation dynamics in human breast cancer cells. J Biol Chem 276(52): 49435-49442, 2001.
45. Liu XF and Bagchi MK: Recruitment of distinct chromatin-modifying complexes by tamoxifen-complexed estrogen receptor at natural target gene promoters in vivo. J Biol Chem 279(15): 15050-8, 2004.
46. Huang Y, Vasilatos SN, Boric L, Shaw PG and Davidson NE: Inhibitors of histone demethylation and histone deacetylation cooperate in regulating gene expression and inhibiting growth in human breast cancer cells. Breast Cancer Res Treat, 2011.
47. Issa JP: DNA methylation as a therapeutic target in cancer. Clin Cancer Res 13(6): 1634-1637, 2007.
48. Claus R and Lubbert M: Epigenetic targets in hematopoietic malignancies. Oncogene 22(42): 6489-6496, 2003. (Pubitemid 37372329)
49. Egger G, Liang G, Aparicio A and Jones PA: Epigenetics in human disease and prospects for epigenetic therapy. Nature 429(6990): 457-463, 2004. (Pubitemid 38715140)
50. Mann BS, Johnson JR, He K, Sridhara R, Abraham S, Booth BP, Verbots L, Morse DE, Jee JM, Pope S, Harapanhalli RS, Dagher R, Farrell A, Justice R and Pazdur R: Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res 13(8): 2318-2322, 2007. (Pubitemid 46698579)
51. Marchion DC, Bicaku E, Turner JG, Schmitt ML, Morelli DR and Munster PN: HDAC2 regulates chromatin plasticity and enhances DNA vulnerability. Mol Cancer Ther 8(4): 794-801, 2009.
52. Munster P, Marchion D, Bicaku E, Lacevic M, Kim J, Centeno B, Daud A, Neuger A, Minton S and Sullivan D: Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Clin Cancer Res 15(7): 2488-2496, 2009.